KV releases Makena performance report

KV Pharmaceutical Co. (NYSE:KVA) said about 2,400 patients started, or are enrolled to begin, treatment with preterm birth drug Makena hydroxyprogesterone caproate from its launch in March through October. The data were included in a performance report for Makena released Wednesday in which KV said it shipped about 7,100 vials to specialty pharmacies/distributors and more than 4,700 vials to doctors and patients. KV has estimated that about 140,000 women per year qualify for Makena's labeled indication in the U.S.: women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. KV was off $0.12 to $1.59 on Wednesday (see BioCentury, April 4). ...